Konstanze Döhner

51.5k total citations · 7 hit papers
272 papers, 16.6k citations indexed

About

Konstanze Döhner is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Konstanze Döhner has authored 272 papers receiving a total of 16.6k indexed citations (citations by other indexed papers that have themselves been cited), including 223 papers in Hematology, 158 papers in Molecular Biology and 89 papers in Genetics. Recurrent topics in Konstanze Döhner's work include Acute Myeloid Leukemia Research (202 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (73 papers) and Chronic Myeloid Leukemia Treatments (72 papers). Konstanze Döhner is often cited by papers focused on Acute Myeloid Leukemia Research (202 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (73 papers) and Chronic Myeloid Leukemia Treatments (72 papers). Konstanze Döhner collaborates with scholars based in Germany, United States and Italy. Konstanze Döhner's co-authors include Hartmut Döhner, Lars Bullinger, Richard F. Schlenk, Axel Benner, Stefan Fröhling, Peter Lichter, Stephan Stilgenbauer, Martin Bentz, Arnold Ganser and Elke Leupolt and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Konstanze Döhner

265 papers receiving 16.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

2000 2.3k citations Hartmut Döhner, Axel Benner et al. profile →
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

2008 1.1k citations Richard F. Schlenk, Konstanze Döhner et al. profile →
Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia

2004 703 citations Lars Bullinger, Konstanze Döhner et al. profile →
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm

2002 660 citations Richard F. Schlenk, Axel Benner et al. Blood profile →
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

2005 603 citations Konstanze Döhner, Richard F. Schlenk et al. Blood profile →
IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication

2010 578 citations Richard F. Schlenk, Lars Bullinger et al. Journal of Clinical Oncology profile →
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways

2017 331 citations Lars Bullinger, Konstanze Döhner et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Konstanze Döhner

Since Specialization

Citations

This map shows the geographic impact of Konstanze Döhner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Konstanze Döhner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Konstanze Döhner more than expected).

Fields of papers citing papers by Konstanze Döhner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Konstanze Döhner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Konstanze Döhner. The network helps show where Konstanze Döhner may publish in the future.

Co-authorship network of co-authors of Konstanze Döhner

This figure shows the co-authorship network connecting the top 25 collaborators of Konstanze Döhner. A scholar is included among the top collaborators of Konstanze Döhner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Konstanze Döhner. Konstanze Döhner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	XPO1-dependency of DEK::NUP214 leukemia 2025 ·Leukemia ·(unknown), Arnold Kloos, (unknown), (unknown), Robert Geffers, (unknown), (unknown), Kerstin Görlich, (unknown), Halyna R. Shcherbata, Michaela Scherr, Konstanze Döhner, Razif Gabdoulline, Michael Heuser	0
2	Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients 2023 ·Leukemia ·Nikolaus Jahn, Maral Saadati, Pierre Fenaux, Marco Gobbi, Gail J. Roboz, Lars Bullinger, Pavlo Lutsik, (unknown), Christoph Plass, Claudia Walter, Karlheinz Holzmann, Yong Hao, Sue Naim, Nicholas Schreck, Julia Krzykalla, Axel Benner, Harold Keer, Mohammad Azab, Konstanze Döhner, Hartmut Döhner	22
3	In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts 2023 ·Leukemia ·Gabriele Greve, Geoffroy Andrieux, Pascal Schlosser, Nadja Blagitko‐Dorfs, (unknown), (unknown), Dietmar Pfeifer, (unknown), Andreas Neubauer, Jürgen Krauter, Michael Heuser, Helmut R. Salih, Konstanze Döhner, Hartmut Döhner, Björn Hackanson, Melanie Boerries, Michael Lübbert	2
4	Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) 2023 ·Leukemia ·Frank Stegelmann, Lino L. Teichmann, Florian H. Heidel, (unknown), Thomas Ernst, Sebastian Kreil, Andreas Reiter, (unknown), Stefanie Schauer, (unknown), (unknown), Susanne Isfort, Hartmut Döhner, Tim H. Brümmendorf, Martin Grießhammer, Konstanze Döhner, Steffen Koschmieder	5
5	Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel 2023 ·American Journal of Hematology ·Farhad Ravandi, Jacqueline Cloos, Francesco Buccisano, Richard Dillon, Konstanze Döhner, Sylvie Freeman, Christopher S. Hourigan, G. J. Ossenkoppele, Gail J. Roboz, Marion Subklewe, Christian Thiede, (unknown), Peter J.M. Valk, Adriano Venditti, Andrew H. Wei, Roland B. Walter, Michael Heuser	10
6	The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial 2023 ·Leukemia ·Johanna Hammersen, Sebastian Birndt, Konstanze Döhner, Philipp A. Reuken, Andreas Stallmach, (unknown), (unknown), Markus Pfirrmann, (unknown), (unknown), Karl Träger, Hinrich Bremer, Salvatore Russo, Gerald Illerhaus, Daniel Drömann, Sven Schneider, Paul La Rosée, Andreas Hochhaus	11
7	Defining disease modification in myelofibrosis in the era of targeted therapy 2022 ·Cancer ·Naveen Pemmaraju, Srđan Verstovšek, Ruben A. Mesa, Vikas Gupta, Jacqueline S. Garcia, Joseph M. Scandura, Stephen T. Oh, Francesco Passamonti, Konstanze Döhner, Adam J. Mead	44
8	TET2 deficiency cooperates with CBFB‐MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event 2022 ·British Journal of Haematology ·Kristian Reckzeh, Montserrat Estruch, Mina Ali, (unknown), (unknown), Kyoung‐Jae Won, Frank G. Rücker, Konstanze Döhner, Kim Theilgaard‐Mönch	2
9	Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia 2020 ·Science ·Hannah J. Uckelmann, (unknown), Eric Wong, Charlie Hatton, Hugh Giovinazzo, Jayant Y. Gadrey, Andrei V. Krivtsov, Frank G. Rücker, Konstanze Döhner, Gerard M. McGeehan, Ross L. Levine, Lars Bullinger, George S. Vassiliou, Scott A. Armstrong	152
10	Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN 2020 ·Leukemia ·Frank Stegelmann, Kai Wille, (unknown), Christiane Fuchs, Stefanie Schauer, Parvis Sadjadian, Tatjana Becker, (unknown), Hartmut Döhner, Rudolf Stadler, (unknown), Konstanze Döhner, Martin Grießhammer	9
11	Genomics of Acute Myeloid Leukemia Diagnosis and Pathways breakdown → 2017 ·Journal of Clinical Oncology ·Lars Bullinger, Konstanze Döhner, Hartmut Döhner	331
12	Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML 2017 ·Clinical Cancer Research ·Frank Reichenbach, (unknown), Enrico Schalk, Diana Becker, (unknown), (unknown), Franziska Todt, Denise Wolleschak, Konstanze Döhner, Jens U. Marquardt, Florian H. Heidel, Frank Edlich	24
13	Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation 2017 ·Leukemia ·(unknown), Benedetto Daniele Giaimo, Peggy Schwarz, Karin Soller, Virág Vas, Marek Bartkuhn, Tamara J. Blätte, Konstanze Döhner, Lars Bullinger, Tilman Borggrefe, Hartmut Geiger, Franz Oswald	20
14	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence 2013 ·Blood ·Ayalew Tefferi, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Kebede H. Begna, Mario Cazzola, Francisco Cervantes, Konstanze Döhner, Heinz Gisslinger, Vikas Gupta, Wang Li, Claire Harrison, Jean‐Jacques Kiladjian, Mary Frances McMullin, Alessandro Rambaldi, Gary J. Schiller, Alessandro M. Vannucchi, Ruben A. Mesa	24
15	PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17) 2013 ·Clinical Cancer Research ·Lars Bullinger, Richard F. Schlenk, Marlies Götz, (unknown), Susanne Hofmann, (unknown), (unknown), Lu Zhang, Vanessa Schneider, Konstanze Döhner, Michael Schmitt, Hartmut Döhner, Jochen Greiner	31
16	Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors 2011 ·Cancer Research ·(unknown), (unknown), (unknown), Christina Holzwarth, (unknown), Sabine Käyser, Konstanze Döhner, Christian Peschel, Robert A.J. Oostendorp, Katharina S. Götze	77
17	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity 2010 ·Blood ·Erdogan Taskesen, Lars Bullinger, Andrea Corbacioglu, Mathijs A. Sanders, Claudia Erpelinck-Verschueren, Bas J. Wouters, (unknown), Frédérik Damm, Jürgen Krauter, Arnold Ganser, Richard F. Schlenk, Bob Löwenberg, Ruud Delwel, Hartmut Döhner, Peter J.M. Valk, Konstanze Döhner	262
18	Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms 2010 ·Haematologica ·Philip Beer, Christina A. Ortmann, Frank Stegelmann, Paola Guglielmelli, John T. Reilly, Thomas Stauffer Larsen, Hans Carl Hasselbalch, (unknown), Per Werner Möller, Konstanze Döhner, Anthony R. Green	17
19	SEURAT: Visual analytics for the integrated analysis of microarray data 2010 ·BMC Medical Genomics ·Alexander Gribov, Martin Sill, (unknown), Frank G. Rücker, Konstanze Döhner, Lars Bullinger, Axel Benner, Antony Unwin	121
20	Inactivating I kappa B epsilon mutations in Hodgkin/Reed–Sternberg cells 2003 ·The Journal of Pathology ·Florian Emmerich, Sebastian Theurich, Michael Hummel, (unknown), (unknown), Konstanze Döhner, Kurt Bommert, Harald Stein, Bernd Dörken	105

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact